Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thickened endometrium · women undergoing fertility treatment
1 finding from 1 review
Intervention not reported
Postoperative delirium (POD) within 7 days (As assessed by any method such as the Mini‐Mental State Examination (MMSE) and Confusion Assessment Method (CAM) in the first week after operation) · adults aged 18 years or over undergoing general anaesthesia for non‐cardiac or non‐neurosurgical elective operations
The intervention probably leads to lower postoperative delirium (POD) within 7 days (As assessed by any… (moderate certainty).
1 finding from 1 review
Intervention not reported
Postoperative cognitive dysfunction (POCD) (As determined by any method of assessing POCD including a battery of neuropsychological tests according to the criteria described by the International Study of Postoperative Cognitive Dysfunction (ISPOCD)) · adults aged 18 years or over undergoing general anaesthesia for non‐cardiac or non‐neurosurgical elective operations
The intervention showed no clear difference in postoperative cognitive dysfunction (POCD) (As determined by any… (moderate certainty).
1 finding from 1 review
Anthropometric measurements: mid‐arm circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Anthropometric measurements: mid‐thigh circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Methotrexate · healthcare staff who handle infusional hazardous drugs
It is very uncertain whether closed‐system transfer device plus safe handling changes methotrexate compared with safe handling alone (very low certainty).
1 finding from 1 review
RR 0.84 [0.58, 1.22]
Studies not reported
Very low